Kalos Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Kalos Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-127	Closed	-$10.6K	–	117
2023 Q2	$10.6K	Hold	127	–	–	0.02%	99
2023 Q1	$9.68K	Hold	127	–	–	0.02%	213
2022 Q4	$10.5K	Buy	+127	New	+$10.3K	0.02%	93
2022 Q1	–	Sell	-2,880	Closed	-$374K	–	305
2021 Q4	$374K	Buy	2,880 +83	+3%	+$10K	0.1%	191
2021 Q3	$364K	Buy	2,797 +309	+12%	+$39.8K	0.1%	186
2021 Q2	$317K	Buy	2,488 +69	+3%	+$9.07K	0.13%	185
2021 Q1	$302K	Sell	2,419 -302	-11%	-$45.2K	0.09%	222
2020 Q4	$460K	Sell	2,721 -709	-21%	-$90.8K	0.2%	139
2020 Q3	$417K	Sell	3,430 -154	-4%	-$17.3K	0.19%	147
2020 Q2	$392K	Sell	3,584 -184	-5%	-$18.1K	0.17%	135
2020 Q1	$388K	Sell	3,768 -808	-18%	-$71.5K	0.17%	133
2019 Q4	$435K	Sell	4,576 -210	-4%	-$18.2K	0.16%	136
2019 Q3	$366K	Buy	4,786 +12	+0.3%	+$997	0.15%	136
2019 Q2	$346K	Buy	4,774 +1,452	+44%	+$124K	0.16%	142
2019 Q1	$300K	Sell	3,322 -1,348	-29%	-$115K	0.19%	112
2018 Q4	$338K	Buy	4,670 +458	+11%	+$36.9K	0.16%	127
2018 Q3	$403K	Sell	4,212 -34	-0.8%	-$3.3K	0.22%	108
2018 Q2	$403K	Buy	+4,246	New	+$390K	0.18%	134
2018 Q1	–	Sell	-4,490	Closed	-$381K	–	219
2017 Q4	$381K	Buy	4,490 +96	+2%	+$8.04K	0.18%	142
2017 Q3	$380K	Sell	4,394 -1,830	-29%	-$147K	0.24%	111
2017 Q2	$480K	Sell	6,224 -298	-5%	-$21.1K	0.44%	73
2017 Q1	$452K	Sell	6,522 -215	-3%	-$14.4K	0.32%	82
2016 Q4	$399K	Sell	6,737 -215	-3%	-$13.3K	0.32%	84
2016 Q3	$461K	Sell	6,952 -14	-0.2%	-$866	0.39%	78
2016 Q2	$377K	Sell	6,966 -1,680	-19%	-$92K	0.29%	106
2016 Q1	$603K	Buy	8,646 +194	+2%	+$10.1K	0.5%	66
2015 Q4	$605K	Buy	+8,452	New	+$576K	0.45%	68

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Kalos Management's XBI Position: Q3 2023 in Review

Kalos Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2023, closing a stake of 127 shares — an estimated $10.6K sold.

Kalos Management first reported a position in XBI in Q4 2015 and held it in 27 quarters. The position peaked at $605K in Q4 2015. 679 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

Kalos Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2023 after selling out during the quarter.
Kalos Management sold 127 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $10.6K.
Kalos Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2015 and held it in 27 quarters.
Kalos Management's State Street SPDR S&P Biotech ETF position peaked at $605K in Q4 2015.
679 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on Kalos Management's 13F filing for Q3 2023.